This Page Is Inserted by IFW Operations and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.

		SIPE			•	
	DEC 0 304	02 3:31PM ENEL	II.S. US PAILDERI		NO EO	11 D E
				es la	• • • • • • • • • • • • • • • • • • • •	
		DEC 0 9 2003 FR			THE PARTY OF THE P	FATER OF AMERICA
The state of the s		9	ment of the DEGIN	PATION	UNITEDS	TATES OF AMERICA
			DECLA DECLA			

	As-a-below-r	emeelijiverijoi(s),†Weijie	rabyideclare that			
		My/Our residence(s); pos	office address(es) and	cluzenship(s)(are a	s stated below my name(s) HAT COLUMN A STATE OF THE PARTY OF THE PAR
		I/We verily believe I am/\ and for which a patent is	ve are the original tirst sought on the invention	entitled:	ntor(s) of the subject matte	
			COLOISOOUINOL	INE DERIVATI	VES FOR INHIBITIN	
	•		NFKAPPA	B-INDUCING I	LINASE	
		and the specification of w	hich is attached	hereto (Aventis Doc	ket No.DEAV2002/0045	US NP)
•		(check one)	was filed on	July 3, 2003 as	U.S. Application Number $f 1$	0/613,482
			and was am	ed and claimed in	if applicable). PCT Int'i Application Numbe	er filed on
L.	:		an	d as amended unde	er PCT Article 19 on	(if any).
		I/We hereby state that I	We have reviewed and	d understand the c	ontents of the above ider	itified specification,
		including the claims as at	ity to disclose to the U.S	s. Patent and Trade	ve. emark Office all information	known to me/us to
		be material to patentabilit	y as defined in 37 C.F.F	ર. 1.58.		
•	⊠,	I/We hereby claim foreign	priority benefits under	Title 35, United Sta	tes Code §119(a)-(d) or 36	5 (b) of any foreign
	_	application(s) for patent of	or inventor's certificate, o	or 365(a) of any PC tes of America, lists	Tinternational application (ed below and having a filing	which designated at a date before that of
		the application on which	priority is claimed 1/W	e have also identifi	ed below any foreign appli non which priority is claime	ication for patent or
		inventors certificate navi	uâ s muă aste derois ai	at of the application	of the following to distinct	•
	Foreign	10229762.2	Germany	03/July/	2002	
	Priority:	Number	Country	Day/Mon	th/Year Filed	•
	Prior		Country	Day/Mon	th/Year Filed	•
	Foreign Appin(s):	Number	Country	Dayrivion		
	\boxtimes	I/We hereby claim the	benefit under Title 35,	United States Co	de §119(e) of any United	States Provisional
	,	application(s) listed belo				
	•	60/423,954	November 5, 2002 Filing Date		4 . ****	
		Number	riling Date			•
	<u> </u>	I/We hereby claim the	benefit under Title 35	5, United States (Code §120 or 385(c) of tates listed below and ins	any United States
	— :	matter of each of the citi	Me At this annication is	not disclosed in mi	a nnor Ubiten States abbiio	aucin in die nielliei
	•	provided by the first par	agraph of Title 35, Un	ited States Code	112, I/We acknowledge t 7, Code of Federal Regul the national or PCT intern	he duty to disclose
•		became available between	terial to patentability as an the filing date of the p	orior application and	I the national or PCT intern	ational filing date of
		this application.			Exchange (n) (n)	
		Application Senal No.	Filina Data	Status /D	atented, Pending)	in the state of th
		Approation Sensi No.	Filling Date	Statue (F	aremos, r chamy, 44.	r
,	IMe hereby	declare that all statement	s made berein of my ow	n knowledge are tn	e and that all statements r	nade on information
	and hallof a	re helieved to he tale: and	further that these states	ments were made v	vith the knowledge that will a 18, United States code §	itul talse statements
	willful false	so made are punisnadie d statements may jeopardize	the validity of the applic	cation or any patent	issued thereon. 19 /8 / 1 %	TOO I, BING BIBE SUCII, 113,
			1 1			
	Inventors(s)	: Additional names	s and signatures are atta	acnea.	•	•
	1 5.4	Stafania Mahu		2 Bull name: Ti	horsten Naumann	
	i. Pull name:)	Stefanie Flohr		Z. Pan gang: 11	J.A.	
	Signature:			Signature:	1/1/8/25/25	
	Date:				10 2003	
		izenship: <u>Germany</u> isel/Switerland			nship: <u>Germany</u> enhain/Germany	
		(City and State/City and Co		Producting: Till T	(City and State/City and Count	ry only)
	P. O. Address:	St. Galler Ring 142		_	m Obergarten 16 3697 Hirzenbain, Germa	
		A M. Allad Rocal Continue	nand	•	NOT CHIPTENDAID (LAYMA	INV

直线工	- "打电性性基础统持行 被基 案	睡日本草花(2000年) (1) 1979年) (1) 12 12 12 12 12 12 12 12 12 12 12 12 12 	"打球链链球链片" 阿爾羅羅	- 注稿種簡度後はは特は「CT製塩酸かっておきご調整整配力
				92222322222222222222222222222222222222
	Market Charles and the control of the state			
	Paid 1	enship; all a series of the se	Date - File	
	Residence:	(City and State/City and Country only)	Country of Crizensn 日本国名を報告者は、日本書籍 H. Residence:	p) A State/City and County only)
	P. O. Address:	City and State City and Country City)	•	nty and state city and country only)
	;		-	
·				
	5. Pull name: _		6. Full name:	
	Signature:		Signature:	
		enship:		p;
	. • Rosiderice:	(City and State/City and Country only)		ty and State/City and Country only)
	P. O. Address:		P. O. Address:	

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206
P.O. Box 6800
Mail Code D-303A
Bridgewater, NJ 08807-0800
Telephone (908) 231-3364
Telefax (908) 231-2626

ម ខេ ម៉ូស៊ី

Aventis Docket No. DEAV2002/0045 US NP

and for which a patent is sought on the invention entitled: PYRAZOLOISOOUINOLINE DERIVATIVES FOR INHIBITING NFKAPPAB-INDUCING KINASE and the specification of which is attached hereto (Aventis Docket No.DEAV2002/0045 US NP) (check one) was filed on July 3, 2003 as U.S. Application Number 10/613,482 and was amended on (if applicable).
was described and claimed in PCT Int'l Application Number
and as amended under PCT Article 19 on (if filed on I/We hereby state that I/We have reviewed and understand the contents of the above identified specification, including the claims as amended by any amendment referred to above. I/We acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 C.F.R. 1.56. I/We hereby claim foreign priority benefits under Title 35, United States Code §119(a)-(d) or 365 (b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one other country other than the United States of America, listed below and having a filing date before that of the application on which priority is claimed. I/We have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed: \boxtimes Foreign 10229762.2 <u>Germany</u> 03/July/2002 Day/Month/Year Filed Priority: Country Prior: Foreign Number Country Day/Month/Year Filed Appln(s): \boxtimes : I/We hereby claim the benefit under Title 35, United States Code §119(e) of any United States Provisional application(s) listed below: 60/423,954 November 5, 2002 Number Filing Date I/We hereby claim the benefit under Title 35, United States Code \$120 or 365(c) of any United States application(s) or international application designating the United States listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code \$112, I/We acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations \$1.56 which became available between the filling date of the prior application and the national or PCT international filling date of this application. this application. Filing Date Application Serial No. Status (Patented, Pending) i/We hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Title 18, United States code §1001, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon. Inventors(s): Additional names and signatures are attached. 1. Full name: Stefanic Flohr 2. Full name: Thorsten Naumann Signature: Date: Date: Country of Citizenship: Germany Country of Citizenship: Germany Residence: Basel/Switerland Residence: Hirzenhain/Germany (City and State/City and Country only) (City and State/City and Country only) P. O. Address: St. Galler Ring 142 P. O. Address: Im Obergarten 16 CH-4054 Basel, Switzerland 63697 Hirzenhain, Germany

The large to the large state of	DEC 9 200	33:32PM	- AYENI	IS.US.PAT	DEPL		iosa (n libinga s.) (a ta-ka ta (azasa)	NQ5	<u> Allee Pas</u>	8.
Financi in		# 12 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	<u></u>		-1314-			enagu.		
						(Interior				
	⊥signitia Li± Lond					Signatus Dive				
一种一种一种一种一种一种一种一种一种一种一种一种一种一种一种一种一种一种一种	Country/of Citiz Residence:	(City and State/	ista in pers			Country of Citiz	enship	State/City and Co		BULT!
	P. O. Address;					P. O. Address;		State/City and Co	,	
•										
U ◆	5. Pull name:	<u> </u>				6. Full name: _				
•						Signature;				
•	Country of Citize Residence:	mship;				Country of Citiz	enship:			
, ,	P. O. Address:	(City and State)				P. O. Address;		tate/City and Cou		

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206
P.O. Box 6800
Mail Code D-303A
Bridgewater, NJ 08807-0800
Telephone (908) 231-3364
Telefax (908) 231-2626

Aventis Docket No. DEAV2002/0045 US NP